Dapagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin reduces reabsorption of filtered glucose and increases urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity.